|Bid||12.13 x 1200|
|Ask||13.08 x 1200|
|Day's Range||12.40 - 13.10|
|52 Week Range||10.60 - 13.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech Bicycle Therapeutics PLC ADS fell 10.7% in their trading debut Thursday, shedding $1.50 in their first hour of trade. The company priced its initial public offering late Wednesday at $14, selling 4.3 million shares to raise $60.2 million. The stock is trading on Nasdaq, under the ticker symbol "BCYC." Proceeds of the deal will be used to fund research and development and for working capital and general corporate purposes.
Bicycle Therapeutics plc priced its initial public offering late Wednesday at $14 per American Depositary Share, selling 4.3 million shares to raise $60.2 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BCYC." Separately, Ideaya Biosciences priced its IPo at $10 a share, selling 5 million shares to raise $50 million. That stock will also start trading later Thursday, under the ticker symbol "IDYA."
Bicycle Therapeutics plc , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions....
Bicycle Therapeutics will issue 4.33 million American depository shares, with each ADS representing one ordinary share of the company, according to the S-1 the company filed May 13. The company expects to price the offering between $14 and $16 and list its ADRs on the Nasdaq under the ticker symbol BCYC. At the midpoint of the estimated price range, the IPO will fetch the company gross proceeds of $64.9 million.